FDA Guidance Raises Prospect Of More INDs For Supplement Research
This article was originally published in The Tan Sheet
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
You may also be interested in...
The development of OTC drugs based on probiotics requires a regulatory system more receptive to research on the microorganisms' use as therapeutic ingredients, according to microbiologist Gary Huffnagle.
FDA says current dietary supplement regulations make clear that citizen petitions can be filed to request approval of ingredients that were studied in clinical trials and were part of unsuccessful investigational new drug applications
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants